Polymerase News and Research

RSS

New interactive map shows spread of avian flu virus

Scientists here have designed a new, interactive map of the spread of the avian flu virus (H5N1) that for the first time incorporates genetic, geographic and evolutionary information that may help predict where the next outbreak of the virus is likely to occur.

1 May 2007

Google maps used to track avian flu spread

An interactive "supermap" that portrays the mutations and spread of the avian flu around the globe over time should help researchers and policy makers better understand the virus and anticipate further outbreaks, according to a new study involving University of Colorado at Boulder and Ohio State University researchers.

1 May 2007

RNA analysis can identify rejection in lung transplant patients

Recent data from the Lung Allograft Rejection Gene expression Observational (LARGO) study provides compelling evidence that profiling gene expression in peripheral blood can detect organ rejection in lung transplant patients.

1 May 2007

Liver center leading record number of studies to tackle hepatitis C

While many research institutions are suffering from funding cuts, Drs. Bruce R. Bacon and Adrian M. Di Bisceglie are chugging away with their usual tenacity.

27 Apr 2007

DuPont settles patent case with Bio-Rad Laboratories

DuPont has announced that it has settled patent infringement litigation against Bio-Rad Industries, Inc. of Hercules, Calif.

27 Apr 2007

New automated test for gene mutations causing fragile X syndrome

A new automated test could enable population screening to identify carriers of the gene mutations causing fragile X syndrome (FXS), the most common inherited form of mental retardation, reports a study in the April issue of Genetics in Medicine, published by the American College of Medical Genetics and Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

19 Apr 2007

Bristol-Myers Squibb announces new results of Baraclude (entecavir) resistance monitoring program

Bristol-Myers Squibb Company has announced new results of the Baraclude (entecavir) resistance monitoring program, which found a continued low incidence of resistance in studies of nucleoside-naive chronic hepatitis B patients through four years of treatment.

16 Apr 2007

Schering-Plough commits to chronic hepatitis C research

Schering-Plough has reaffirmed its commitment to advancing the science and treatment of chronic hepatitis C virus (HCV) infection with several key data presentations at the European Association for the Study of the Liver (EASL) 42nd annual meeting in Barcelona, Spain, April 11-15.

11 Apr 2007

Unusual protein helps cell bypass damage when making new DNA

Scientists have discovered how an unusual protein helps a cell bypass damage when making new DNA, thereby averting the cell's self-destruction.

3 Apr 2007

Decoy receptor 3 expressed in rheumatic synovial fibroblasts protects the cells against Fas-induced apoptosis

A complex autoimmune disease, rheumatoid arthritis (RA) is characterized by chronic inflammation and progressive joint damage. This process begins with hyperplasia, or excessive increase in size and thickness, of synovial tissue. Along with provoking cartilage and bone destruction, this abnormal tissue growth is resistant to apoptosis, the natural cell death vital to the generation of healthy new cells.

30 Mar 2007

FDA clears Xpert EV test for meningitis

The U.S. Food and Drug Administration (FDA) has cleared for marketing a test that uses molecular biology to quickly detect the presence of viral meningitis.

19 Mar 2007

First 3-D structure from key influenza protein revealed

In 1918, 50 million people died during a worldwide influenza pandemic caused by mutation of a bird-specific strain of the influenza virus. Recently H5N1, another highly infectious avian strain has caused outbreaks of bird flu around the world.

27 Feb 2007

ViroPharma receives orphan drug designation for Maribavir

ViroPharma Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for maribavir for prevention of cytomegalovirus (CMV) viremia and disease in the populations at-risk.

7 Feb 2007

Ultrasensitive optical sensor detects viruses fast

Scientists of the Biophysical Engineering Group of the University of Twente in The Netherlands have developed an ultrasensitive sensor that can be used in a handheld device to, within minutes, detect various viruses and measure their concentration.

22 Jan 2007

A fully integrated microfluidic genetic analysis system with sample-in-answer-out capability

In an accomplishment that represents a significant step toward an era of rapid, inexpensive, bedside testing for cancer, researchers at the University of Virginia have developed a microfluidic device that can process human blood samples and yield diagnostic results within an hour.

8 Jan 2007

Biofunctional organic nanocrystals for quantitative detection of pathogen deoxyribonucleic acid

Waiting a day or more to get lab results back from the doctor's office soon could become a thing of a past.

4 Dec 2006

Indian state to tackle workplace HIV discrimination

India's wealthiest state, Maharashtra is about to become the first state to introduce a policy which aims to attack the discrimination suffered by those infected with HIV in the workplace.

20 Nov 2006

Scientists shed light on the roll of junk DNA

University of Iowa scientists have made a discovery that broadens understanding of a rapidly developing area of biology known as functional genomics and sheds more light on the mysterious, so-called "junk DNA" that makes up the majority of the human genome.

13 Nov 2006

Detecting rare microRNAs with gold nanoparticles

Over the past three years, numerous studies have shown that short pieces of single-stranded RNA, known as microRNAs, play a central role in the development of at least some cancers.

30 Oct 2006

Bristol-Myers Squibb and Medivira announce collaboration to commercialize HIV treatment

Bristol-Myers Squibb and Medivir AB have announced a worldwide collaboration to develop and commercialize MIV-170, a preclinical non-nucleoside reverse transcriptase inhibitor, or NNRTI, intended for the treatment of HIV-1 infection in adults as part of an antiretroviral drug regimen.

13 Sep 2006